Evidence map›Paper›PMID 42346230›Full record

ArticleCurrent oncology (Toronto, Ont.)2026

Consensus Statement from the Society of Gynecologic Oncology of Canada on Folate Receptor α Testing in Ovarian Cancer.

Kim Ma, Basile Tessier-Cloutier, Alon D Altman, Mark S Carey, Josee-Lyne Ethier, Susie Lau, Cheng-Han Lee, Laura Hopkins, Katharina Kieser, Aalok Kumar and 16 more

Abstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Kim MaDivision of Gynecologic Oncology, Jewish General Hospital, McGill University, Montréal, QC H3T 1E2, Canada.
Basile Tessier-CloutierFaculty of Medicine and Health Sciences, McGill University, Montréal, QC H4A 3J1, Canada.ORCID 0000-0001-8739-3879
Alon D AltmanMax Rady College of Medicine, Obstetrics, Gynecology and Reproductive Sciences, WN50014-Women's Hospital, University of Manitoba, Winnipeg, MB R3A 1R9, Canada.ORCID 0000-0002-6345-4910
Mark S CareyDivision of Gynecologic Oncology, Vancouver Coastal Health; Department of Obstetrics and Gynecology, Faculty of Medicine, University of British Columbia, Vancouver, BC V6H 3N1, Canada.
Josee-Lyne EthierDepartment of Medicine, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON M4N 3M5, Canada.
Susie LauDivision of Gynecologic Oncology, Jewish General Hospital, McGill University, Montréal, QC H3T 1E2, Canada.
Cheng-Han LeeDepartment of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB T6G 1C9, Canada.
Laura HopkinsDivision of Gynecologic Oncology, Saskatoon Cancer Centre, Saskatoon, SK S7N 5B8, Canada.
Katharina KieserDivision of Gynaecologic Oncology, Dalhousie University, Halifax, NS B3H 1V7, Canada.
Aalok KumarBC Cancer-Surrey, University of British Columbia, Vancouver, BC V3V 1Z2, Canada.
Shuk On Annie LeungMcGill University Health Centre, Montreal, QC H4A 3J1, Canada.ORCID 0000-0003-4110-7595
Julie M V NguyenDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, McMaster University, Hamilton, ON L8S 4K1, Canada.
Helen MacKayDepartment of Medicine, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON M4N 3M5, Canada.
Jacob McGeeDepartment of Obstetrics and Gynecology, London Health Sciences Centre and Schulich School of Medicine and Dentistry, Western University, London, ON N6A 5W9, Canada.ORCID 0000-0003-3210-0682
Lina SalmanDepartment of Obstetrics and Gynecology, London Health Sciences Centre and Schulich School of Medicine and Dentistry, Western University, London, ON N6A 5W9, Canada.
Shannon SalvadorDivision of Gynecologic Oncology, Jewish General Hospital, McGill University, Montréal, QC H3T 1E2, Canada.ORCID 0000-0002-8061-375X
Cidalia SluceSociety of Gynecologic Oncology of Canada, Ottawa, ON K1H 8K3, Canada.
Luiza TatarMcGill University Health Centre, Montreal, QC H4A 3J1, Canada.ORCID 0009-0000-2581-3209
Alicia A ToneOvarian Cancer Canada, Toronto, ON M2P 2A9, Canada.ORCID 0000-0001-9715-4273
Anna TinkerDivision of Gynecologic Oncology, Vancouver Coastal Health; Department of Obstetrics and Gynecology, Faculty of Medicine, University of British Columbia, Vancouver, BC V6H 3N1, Canada.
Elizabeth TremblayDivision of Gynecologic Oncology, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, QC H2X 0A9, Canada.ORCID 0000-0003-3152-0765
Ana C VenezianiDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C4, Canada.
Danielle VicusDivision of Gynecologic Oncology, Department of Gynecology and Obstetrics, University of Toronto, Toronto, ON M5G 1E2, Canada.
Stephen WelchDepartment of Medicine, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON M4N 3M5, Canada.
Sharon Windsor HarkerWindsor Medical Communications, Inc., Hamilton, ON L8N 1Z6, Canada.ORCID 0009-0001-2847-9856
Melica Nourmoussavi BrodeurDivision of Gynecologic Oncology, Jewish General Hospital, McGill University, Montréal, QC H3T 1E2, Canada.ORCID 0000-0002-7595-0313

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFolate receptor alpha (FRα), commonly expressed in epithelial ovarian cancers, is a clinically actionable biomarker following approval of the antibody-drug conjugate mirvetuximab soravtansine (MIRV). Pivotal trials showed that high FRα expression predicts MIRV benefit, creating the need for standardized testing to ensure timely, equitable access.

methodsTo address the need for guidance on FRα testing, the Society of Gynecologic Oncology of Canada convened a multidisciplinary Expert Panel to review the evidence and integrate Canadian clinical, pathology, laboratory, and patient perspectives. Consensus recommendations were developed through structured evidence review, expert discussion, iterative revision, and patient partner input.

resultsThe panel issued recommendations on the clinical role and timing of FRα testing, tissue requirements, assay selection and validation, interpretation and reporting standards, laboratory quality assurance, reimbursement, and equitable access. It is recommended that FRα testing be available to all patients with epithelial ovarian cancer, with results available no later than platinum-resistant disease, using a validated assay, preferably the Ventana FOLR1 RxDx assay or an appropriately validated laboratory-developed test. Standardized synoptic reporting, participation in external quality assurance programs, and clear patient communication were deemed essential.

conclusionsThese recommendations aim to promote integrated, equitable, standardized FRα testing across Canada and support timely identification of patients eligible for FRα-directed therapy, clinical trial enrollment, and future biomarker-driven treatment strategies.

Indexed as

Carcinoma, Ovarian EpithelialFolate Receptor 1Ovarian NeoplasmsAntibodies, Monoclonal, HumanizedBiomarkers, TumorCanadaFemaleHumansImmunoconjugatesMaytansineAntibodies, Monoclonal, HumanizedBiomarkers, TumorFolate Receptor 1ImmunoconjugatesMaytansinemirvetuximab soravtansinecompanion diagnosticsconsensus statementepithelial ovarian cancerfolate receptor alphamirvetuximab soravtansine

Identifiers

PMID42346230
PMCPMC13298061

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.